Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C N Harrison

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Leukemia|May 6, 2017
Equivalence of BCSH and WHO diagnostic criteria for ETC N Harrison, M F McMullin, A R Green, et al.
British Journal of Haematology|September 1, 1996
Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpuraC N Harrison, A S Lawrie, A Iqbal, et al.
Thrombosis and Haemostasis|June 1, 2002
Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosisC N Harrison, S Donohoe, P Carr, et al.
Lancet (London, England)|June 26, 2001
Antenatal antibody screeningH V New, C N Harrison, C H Rodeck, et al.
European Journal of Haematology|February 28, 2002
Lack of pathogenic mutations in the 5'-untranslated region of the thrombopoietin gene in patients with non-familial essential thrombocythaemiaA J Allen, R E Gale, C N Harrison, et al.
British Journal of Haematology|September 30, 1998
The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemiaC N Harrison, R E Gale, A C Wiestner, et al.
British Journal of Haematology|October 16, 1999
Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic valueC N Harrison, R E Gale, F Pezella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant RegistryC D Williams, C N Harrison, T A Lister, et al.
Leukemia|October 20, 2023
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohortJ M O'Sullivan, J Taylor, A Gerds, et al.
British Journal of Cancer|October 3, 1999
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AMLC N Harrison, W Gregory, G V Hudson, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Leukemia|May 6, 2017
Equivalence of BCSH and WHO diagnostic criteria for ETC N Harrison, M F McMullin, A R Green, et al.
British Journal of Haematology|September 1, 1996
Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpuraC N Harrison, A S Lawrie, A Iqbal, et al.
Thrombosis and Haemostasis|June 1, 2002
Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosisC N Harrison, S Donohoe, P Carr, et al.
Lancet (London, England)|June 26, 2001
Antenatal antibody screeningH V New, C N Harrison, C H Rodeck, et al.
European Journal of Haematology|February 28, 2002
Lack of pathogenic mutations in the 5'-untranslated region of the thrombopoietin gene in patients with non-familial essential thrombocythaemiaA J Allen, R E Gale, C N Harrison, et al.
British Journal of Haematology|September 30, 1998
The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemiaC N Harrison, R E Gale, A C Wiestner, et al.
British Journal of Haematology|October 16, 1999
Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic valueC N Harrison, R E Gale, F Pezella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant RegistryC D Williams, C N Harrison, T A Lister, et al.
Leukemia|October 20, 2023
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohortJ M O'Sullivan, J Taylor, A Gerds, et al.
British Journal of Cancer|October 3, 1999
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AMLC N Harrison, W Gregory, G V Hudson, et al.
Pageof 3